Renate Gorenflo
Family · Snyder, NYNPI 1407061328
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 345 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $88.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AstraZeneca$3K
- Daiichi Sankyo Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- GSK$1K
- Pharmacosmos Therapeutics Inc.$931
- plus $18K from 53 others
What the payments were for
- Food & beverage$30,320100%
- Education$1400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,460 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $10,606 |
| Oxycodone Hcl | 158 | $913 |
| Ondansetron OdtOndansetron | 95 | $689 |
| Tramadol Hcl | 158 | $354 |
| Celecoxib | 21 | $269 |
| Pantoprazole Sodium | 26 | $135 |
| Meloxicam | 59 | $126 |
| Naproxen | 12 | $95 |
| Cephalexin | 24 | $67 |
| Metoclopramide Hcl | 14 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $10,60632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Snyder
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.